ストックスクリーナーアプリを入手
7.885
3.33%
-0.245
前日終値:
$8.13
開ける：
$7.9
24時間の取引高:
3.17M
Relative Volume:
0.27
時価総額：
$8.33B
収益：
$140.98M
当期純損益:
$-854.60M
株価収益率:
-9.233
EPS:
-0.854
ネットキャッシュフロー:
$-299.31M
1週間 パフォーマンス:
+2.73%
1か月 パフォーマンス:
+4.86%
6か月 パフォーマンス:
-9.67%
1年 パフォーマンス:
+247.75%
1日の値動き範囲:
$7.74
$7.99
1週間の範囲:
$7.4301
$8.27
52週間の値動き範囲:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Compare IBRX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.855 | 8.62B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
546.08 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.35 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.44 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
140.66 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.58 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
すべてを表示
Immunitybio Inc (IBRX) 最新ニュース
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
ImmunityBio (NASDAQ:IBRX): What Could Shape Its Next Move? - Kalkine Media
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Patrick Soon-Shiong to Thomas Ichim: Thanks for Sharing Important Difference Between Il-2 and Il-15 - Oncodaily
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Class A - The National Law Review
ImmunityBio (IBRX) Shares Moved, What Is Behind The Fresh Attention? - Sahm
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc. - MarketBeat
Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)? - simplywall.st
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales - Stocktwits
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
ImmunityBio, Inc. (IBRX) options chain - Yahoo Finance UK
ImmunityBio, Inc. • Robinhood Token (IBRX) Price Prediction for 2026 to 2031 - bybit.com
Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus - FinancialContent
ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach - Sahm
ImmunityBio Names Former World Bank President Jim Yong Kim Vice Chairman - citybiz
ImmunityBio appoints Jim Yong Kim as vice chairman - Investing.com
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman - ImmunityBio
Royal Bank of Canada Has $11.40 Million Holdings in ImmunityBio, Inc. $IBRX - MarketBeat
Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next - webull.com
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken In - The National Law Review
Analysts Have Been Trimming Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target After Its Latest Report - 富途牛牛
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns - finance.yahoo.com
ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value - Sahm
The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses - Yahoo Finance
ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake - Stock Titan
Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright - MarketBeat
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake - Yahoo Finance
HC Wainwright Increases Earnings Estimates for ImmunityBio - MarketBeat
ImmunityBio | 10-Q: Q2 2026 Earnings Report - Moomoo
ImmunityBio Releases Q2 2026 Financial Results - AlphaStreet
ImmunityBio (NASDAQ:IBRX) Posts Earnings Results, Misses Estimates By $0.14 EPS - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings - MarketBeat
ImmunityBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Immunitybio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Immunitybio Inc earnings missed by $0.14, revenue topped estimates - Investing.com
Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M - marketscreener.com
ImmunityBio 2Q 2026: Revenue $51.24M, EPS ($0.22) — 10-Q Summary - tradingview.com
[10-Q] ImmunityBio, Inc. Quarterly Earnings Report - Stock Titan
ImmunityBio: Q2 Earnings Snapshot - Barchart.com
ImmunityBio posts Q2 2026 product revenue $50.7M; H1 revenue $94.8M, cash $357.4M - TradingView
ImmunityBio Q2 revenue rises 92% to record $50.7 million - Quiver Quantitative
Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX) - Stock Titan
ImmunityBio, Inc. (IBRX) Q2 2026 Earnings - 24/7 Wall St.
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million - Business Wire
ImmunityBio, Inc. (IBRX) Stock Analysis: Assessing a 78% Potential Upside in Cutting-Edge Immunotherapy - directorstalkinterviews.com
Weekly Recap: U.S. papillary-only label expansion and UAE ANKTIVA approval - TradingView
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
5.00%
大文字化:
|
ボリューム (24 時間):